


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-41. (Cancelled)

42. (Currently Amended) A method of treating arthritis, ~~an inflammatory disease~~, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of the following formula:



Formula I


wherein:

n is 0 or 1;


q is 1;

X is O or NH;

A is a natural or unnatural amino acid of Formula IIa-i:



B is a hydrogen atom, a deuterium atom, C₁₋₁₀ straight chain or branched alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), (CH₂)_mheteroaryl, halomethyl, CO₂R¹³, CONR¹⁴R¹⁵, CH₂ZR¹⁶, CH₂OCO(aryl), CH₂OCO(substituted aryl), CH₂OCO(heteroaryl), CH₂OCO(substituted heteroaryl), or CH₂OPO(R¹⁷)R¹⁸, where Z is an oxygen or a sulfur atom, or B is a group of the Formula IIIa-c:



R¹ is substituted phenyl, naphthyl, or substituted naphthyl;

R² is hydrogen, lower alkyl, (CH₂)_pCO₂R³, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mtetrazolyl;

R^3 is hydrogen or lower alkyl;

and wherein:

R^4 is alkyl, cycloalkyl, phenyl, substituted phenyl, $(CH_2)_mNH_2$, $(CH_2)_mNHCOR^{10}$, $(CH_2)_mN(C=NH)NH_2$, $(CH_2)_pCO_2R^3$, $(CH_2)_pOR^{11}$, $(CH_2)_pSR^{12}$, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or $(CH_2)_m$ heteroaryl, wherein heteroaryl includes (but is not limited to) pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

R^{4a} is hydrogen, or methyl, or R^4 and R^{4a} taken together are $-(CH_2)_d-$ where d is an interger from 2 to 6;

R^5 is phenyl, substituted phenyl, $(CH_2)_p$ phenyl, $(CH_2)_p$ (substituted phenyl), cycloalkyl, or benzofused cycloalkyl;

R^6 is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^7 is hydrogen, fluorine, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR^{11} , SR^{12} , or $NHCOR^{10}$;

R^8 is hydrogen, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^9 is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or COR^{10} ;

R^{10} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR^{13} , or $NR^{14}R^{15}$;

R^{11} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{12} is alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{13} is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{14} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{15} is hydrogen or alkyl; or

R^{14} and R^{15} taken together form a five, six or seven membered carbocyclic or heterocyclic ring, such as morpholine or N-substituted piperazine;

R^{16} is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or $(CH_2)_m$ heteroaryl;

R^{17} and R^{18} are independently alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, or phenylalkyl, substituted phenylalkyl, or (cycloalkyl)alkyl;

R^{19} and R^{20} are independently hydrogen, alkyl, phenyl, substituted phenyl, $(CH_2)_m$ phenyl, or $(CH_2)_m$ (substituted phenyl), or R^{19} and R^{20} taken together are $-(CH=CH)_2-$;

R^{21} is hydrogen, alkyl, phenyl, substituted phenyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl);

R^{22} , R^{23} and R^{24} are independently hydrogen or alkyl;

Y^1 is CH_2 , $(CH_2)_2$, $(CH_2)_3$, or S;

Y^2 is O or NR^{24} ;

Y^3 is CH_2 , O, or NR^{24} ;

a is 0 or 1 and b is 1 or 2, provided that when a is 1 then b is 1;

c is 1 or 2, provided that when c is 1 then a is 0 and b is 1;


m is 1, 2, 3 or 4; and

p is 1 or 2;

or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

43-50. (Cancelled)

51. (New) A method of treating hepatitis, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of the following formula:



Formula I


wherein:

n is 0 or 1;


q is 1;

X is O or NH;


A is a natural or unnatural amino acid of Formula IIa-i:




IIa




IIb




IIc




IIId




IIe




IIIf



IIig




IIih



IIii

B is a hydrogen atom, a deuterium atom, C₁₋₁₀ straight chain or branched alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), (CH₂)_mheteroaryl, halomethyl, CO₂R¹³, CONR¹⁴R¹⁵, CH₂ZR¹⁶, CH₂OCO(aryl), CH₂OCO(substituted aryl), CH₂OCO(heteroaryl), CH₂OCO(substituted heteroaryl), or CH₂OPO(R¹⁷)R¹⁸, where Z is an oxygen or a sulfur atom, or B is a group of the Formula IIIa-c:



R¹ is substituted phenyl, naphthyl, or substituted naphthyl;

R² is hydrogen, lower alkyl, (CH₂)_pCO₂R³, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mtetrazolyl;

R³ is hydrogen or lower alkyl;

and wherein:

R⁴ is alkyl, cycloalkyl, phenyl, substituted phenyl, (CH₂)_mNH₂, (CH₂)_mNHCOR¹⁰, (CH₂)_mN(C=NH)NH₂, (CH₂)_pCO₂R³, (CH₂)_pOR¹¹, (CH₂)_pSR¹², (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mheteroaryl, wherein heteroaryl includes (but is not limited to) pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

R^{4a} is hydrogen, or methyl, or R⁴ and R^{4a} taken together are -(CH₂)_d- where d is an interger from 2 to 6;

R⁵ is phenyl, substituted phenyl, (CH₂)_pphenyl, (CH₂)_p(substituted phenyl), cycloalkyl, or benzofused cycloalkyl;

R⁶ is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R^7 is hydrogen, fluorine, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR^{11} , SR^{12} , or $NHCOR^{10}$;

R^8 is hydrogen, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^9 is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or COR^{10} ;

R^{10} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR^{13} , or $NR^{14}R^{15}$;

R^{11} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{12} is alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{13} is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{14} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{15} is hydrogen or alkyl; or

R^{14} and R^{15} taken together form a five, six or seven membered carbocyclic or heterocyclic ring, such as morpholine or N-substituted piperazine;

R^{16} is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or $(CH_2)_m$ heteroaryl;

R^{17} and R^{18} are independently alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, or phenylalkyl, substituted phenylalkyl, or (cycloalkyl)alkyl;

R^{19} and R^{20} are independently hydrogen, alkyl, phenyl, substituted phenyl, $(CH_2)_m$ phenyl, or $(CH_2)_m$ (substituted phenyl), or R^{19} and R^{20} taken together are $-(CH=CH)_2-$;

R^{21} is hydrogen, alkyl, phenyl, substituted phenyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl);

R^{22} , R^{23} and R^{24} are independently hydrogen or alkyl;

Y^1 is CH_2 , $(CH_2)_2$, $(CH_2)_3$, or S;

Y^2 is O or NR^{24} ;

Y^3 is CH_2 , O, or NR^{24} ;

a is 0 or 1 and b is 1 or 2, provided that when a is 1 then b is 1;

c is 1 or 2, provided that when c is 1 then a is 0 and b is 1;

m is 1, 2, 3 or 4; and

p is 1 or 2;

or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.